177 related articles for article (PubMed ID: 32076894)
1. Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.
Riglet F; Mentre F; Veyrat-Follet C; Bertrand J
AAPS J; 2020 Feb; 22(2):50. PubMed ID: 32076894
[TBL] [Abstract][Full Text] [Related]
2. Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer.
Desmée S; Mentré F; Veyrat-Follet C; Sébastien B; Guedj J
BMC Med Res Methodol; 2017 Jul; 17(1):105. PubMed ID: 28716060
[TBL] [Abstract][Full Text] [Related]
3. Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.
Desmée S; Mentré F; Veyrat-Follet C; Guedj J
AAPS J; 2015 May; 17(3):691-9. PubMed ID: 25739818
[TBL] [Abstract][Full Text] [Related]
4. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.
Coley RY; Zeger SL; Mamawala M; Pienta KJ; Carter HB
Eur Urol; 2017 Jul; 72(1):135-141. PubMed ID: 27523594
[TBL] [Abstract][Full Text] [Related]
6. Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases.
de Charry F; Colomban O; You B; Ruffion A; Paparel P; Wilbaux M; Tod M; Freyer G; Perrin P
Clin Genitourin Cancer; 2016 Jun; 14(3):210-217.e1. PubMed ID: 26804605
[TBL] [Abstract][Full Text] [Related]
7. Robust non-linear mixed modelling of longitudinal PSA levels after prostate cancer treatment.
Subtil F; Rabilloud M
Stat Med; 2010 Feb; 29(5):573-87. PubMed ID: 20049769
[TBL] [Abstract][Full Text] [Related]
8. Real-time individual predictions of prostate cancer recurrence using joint models.
Taylor JM; Park Y; Ankerst DP; Proust-Lima C; Williams S; Kestin L; Bae K; Pickles T; Sandler H
Biometrics; 2013 Mar; 69(1):206-13. PubMed ID: 23379600
[TBL] [Abstract][Full Text] [Related]
9. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
Osses DF; Remmers S; Schröder FH; van der Kwast T; Roobol MJ
Eur Urol; 2019 Mar; 75(3):374-377. PubMed ID: 30420254
[TBL] [Abstract][Full Text] [Related]
10. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
[TBL] [Abstract][Full Text] [Related]
12. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
13. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
14. Joint models for dynamic prediction in localised prostate cancer: a literature review.
Parr H; Hall E; Porta N
BMC Med Res Methodol; 2022 Sep; 22(1):245. PubMed ID: 36123621
[TBL] [Abstract][Full Text] [Related]
15. Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.
Nakajima K; Heilbrun LK; Hogan V; Smith D; Heath E; Raz A
Oncotarget; 2016 Dec; 7(50):82266-82272. PubMed ID: 27741512
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
[TBL] [Abstract][Full Text] [Related]
17. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
Pauler DK; Finkelstein DM
Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
[TBL] [Abstract][Full Text] [Related]
18. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach.
Proust-Lima C; Taylor JM
Biostatistics; 2009 Jul; 10(3):535-49. PubMed ID: 19369642
[TBL] [Abstract][Full Text] [Related]
20. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
